CN103288758A - 一种达克米替尼的制备方法 - Google Patents
一种达克米替尼的制备方法 Download PDFInfo
- Publication number
- CN103288758A CN103288758A CN2013101807526A CN201310180752A CN103288758A CN 103288758 A CN103288758 A CN 103288758A CN 2013101807526 A CN2013101807526 A CN 2013101807526A CN 201310180752 A CN201310180752 A CN 201310180752A CN 103288758 A CN103288758 A CN 103288758A
- Authority
- CN
- China
- Prior art keywords
- amino
- preparation
- buddhist nun
- grammeter
- methoxyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 title abstract description 6
- 229950002205 dacomitinib Drugs 0.000 title abstract description 6
- 238000006482 condensation reaction Methods 0.000 claims abstract description 13
- YSEMCVGMNUUNRK-UHFFFAOYSA-N 3-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1 YSEMCVGMNUUNRK-UHFFFAOYSA-N 0.000 claims abstract description 9
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000005917 acylation reaction Methods 0.000 claims abstract description 4
- 238000006266 etherification reaction Methods 0.000 claims abstract description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- 239000002585 base Substances 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- -1 3-chloro-4-fluorophenyl Chemical group 0.000 claims description 10
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 claims description 5
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 3
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 claims description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 3
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 claims description 3
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims description 2
- 239000012964 benzotriazole Substances 0.000 claims description 2
- 229940043232 butyl acetate Drugs 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229960001701 chloroform Drugs 0.000 claims description 2
- 229940093499 ethyl acetate Drugs 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 2
- 229940011051 isopropyl acetate Drugs 0.000 claims description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 4
- XPJWCVLKRVTORQ-UHFFFAOYSA-N 4-piperidin-1-ylbut-2-enoyl chloride Chemical compound ClC(=O)C=CCN1CCCCC1 XPJWCVLKRVTORQ-UHFFFAOYSA-N 0.000 abstract 1
- 230000003321 amplification Effects 0.000 abstract 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 abstract 1
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000007787 solid Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 238000009833 condensation Methods 0.000 description 7
- 230000005494 condensation Effects 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 238000010792 warming Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 238000005660 chlorination reaction Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000006198 methoxylation reaction Methods 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- 238000005292 vacuum distillation Methods 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000012973 diazabicyclooctane Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZYKVRFMMRAPHAZ-UHFFFAOYSA-N 7-fluoro-3 Chemical compound C1S(=O)(=O)CC(C=2)=CC(F)=CC=2CS(=O)(=O)CC2=CC=C1C=C2 ZYKVRFMMRAPHAZ-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 239000005785 Fluquinconazole Substances 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 101500025419 Homo sapiens Epidermal growth factor Proteins 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002608 ionic liquid Substances 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310180752.6A CN103288758B (zh) | 2013-05-16 | 2013-05-16 | 一种达克米替尼的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310180752.6A CN103288758B (zh) | 2013-05-16 | 2013-05-16 | 一种达克米替尼的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103288758A true CN103288758A (zh) | 2013-09-11 |
CN103288758B CN103288758B (zh) | 2015-01-21 |
Family
ID=49090346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310180752.6A Expired - Fee Related CN103288758B (zh) | 2013-05-16 | 2013-05-16 | 一种达克米替尼的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103288758B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014183560A1 (zh) * | 2013-05-16 | 2014-11-20 | 苏州明锐医药科技有限公司 | 阿法替尼及其中间体的制备方法 |
CN106008372A (zh) * | 2016-03-16 | 2016-10-12 | 江苏悦兴药业有限公司 | 一种达克米替尼的制备方法及其关键中间体 |
CN112375043A (zh) * | 2020-11-26 | 2021-02-19 | 江苏食品药品职业技术学院 | 一种制备达克替尼的方法 |
CN113004212A (zh) * | 2019-12-20 | 2021-06-22 | 上海天慈国际药业有限公司 | 一种达克替尼的制备方法 |
CN113045504A (zh) * | 2019-12-27 | 2021-06-29 | 上海天慈国际药业有限公司 | 一种达克替尼的制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050250761A1 (en) * | 2004-05-06 | 2005-11-10 | Pfizer Inc | 4-Phenylamino-quinazolin-6-yl-amides |
CN101094840A (zh) * | 2004-12-29 | 2007-12-26 | 韩美药品株式会社 | 抑制癌细胞生长的喹唑啉衍生物和制备其的方法 |
CN101357905A (zh) * | 2007-08-01 | 2009-02-04 | 上海艾力斯医药科技有限公司 | 4-[3-氯-4-(3-氟-苄氧基)-苯胺基]-6-取代胺基-喹唑啉衍生物的制备方法 |
CN101570516A (zh) * | 2009-04-14 | 2009-11-04 | 重庆威尔德·浩瑞医药化工有限公司 | 一种制备4-(3-氯-4-氟苯基胺基)-7-甲氧基-6-[3-(4-吗啉基)丙氧基]喹唑啉的方法 |
CN102942529A (zh) * | 2012-11-09 | 2013-02-27 | 贵州大学 | 4-(4-取代哌嗪)-5,6,7-三烷氧基喹唑啉类化合物及其制备方法和应用 |
-
2013
- 2013-05-16 CN CN201310180752.6A patent/CN103288758B/zh not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050250761A1 (en) * | 2004-05-06 | 2005-11-10 | Pfizer Inc | 4-Phenylamino-quinazolin-6-yl-amides |
CN101094840A (zh) * | 2004-12-29 | 2007-12-26 | 韩美药品株式会社 | 抑制癌细胞生长的喹唑啉衍生物和制备其的方法 |
CN101357905A (zh) * | 2007-08-01 | 2009-02-04 | 上海艾力斯医药科技有限公司 | 4-[3-氯-4-(3-氟-苄氧基)-苯胺基]-6-取代胺基-喹唑啉衍生物的制备方法 |
CN101570516A (zh) * | 2009-04-14 | 2009-11-04 | 重庆威尔德·浩瑞医药化工有限公司 | 一种制备4-(3-氯-4-氟苯基胺基)-7-甲氧基-6-[3-(4-吗啉基)丙氧基]喹唑啉的方法 |
CN102942529A (zh) * | 2012-11-09 | 2013-02-27 | 贵州大学 | 4-(4-取代哌嗪)-5,6,7-三烷氧基喹唑啉类化合物及其制备方法和应用 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014183560A1 (zh) * | 2013-05-16 | 2014-11-20 | 苏州明锐医药科技有限公司 | 阿法替尼及其中间体的制备方法 |
CN106008372A (zh) * | 2016-03-16 | 2016-10-12 | 江苏悦兴药业有限公司 | 一种达克米替尼的制备方法及其关键中间体 |
CN106008372B (zh) * | 2016-03-16 | 2019-01-15 | 江苏悦兴药业有限公司 | 一种达克米替尼的制备方法及其关键中间体 |
CN113004212A (zh) * | 2019-12-20 | 2021-06-22 | 上海天慈国际药业有限公司 | 一种达克替尼的制备方法 |
CN113045504A (zh) * | 2019-12-27 | 2021-06-29 | 上海天慈国际药业有限公司 | 一种达克替尼的制备方法 |
CN112375043A (zh) * | 2020-11-26 | 2021-02-19 | 江苏食品药品职业技术学院 | 一种制备达克替尼的方法 |
CN112375043B (zh) * | 2020-11-26 | 2022-03-08 | 江苏食品药品职业技术学院 | 一种制备达克替尼的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103288758B (zh) | 2015-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103288758A (zh) | 一种达克米替尼的制备方法 | |
CN103288808B (zh) | 一种阿法替尼的制备方法 | |
CN104262232B (zh) | 尼泰达尼的制备方法 | |
CN105330643B (zh) | 卡比替尼的制备方法 | |
CN104402862B (zh) | 艾立替尼的制备方法 | |
CN102584795B (zh) | 一种克里唑替尼的制备方法 | |
CN103242303A (zh) | 阿法替尼的制备方法 | |
CN106866501A (zh) | 一种盐酸左布比卡因的制备方法 | |
CN110183367A (zh) | 一种适用于产业化的(3r,4s)-1-苄氧羰基-4-乙基吡咯-3-羧酸的合成方法 | |
CN103288804A (zh) | 一种尼洛替尼的制备方法 | |
CN107098849A (zh) | 一种盐酸左布比卡因的制备方法 | |
CN103265482A (zh) | 博舒替尼的制备方法 | |
CN103265530A (zh) | 来那替尼的制备方法 | |
CN103254183B (zh) | 阿法替尼的制备方法 | |
CN104311485A (zh) | 一种治疗白血病的药物博舒替尼的制备方法 | |
CN106008372B (zh) | 一种达克米替尼的制备方法及其关键中间体 | |
CN103288759A (zh) | 达克米替尼的制备方法 | |
CN105523957B (zh) | 一锅法制备拉科酰胺的方法 | |
CN103242244B (zh) | 一种卡奈替尼的制备方法 | |
CN107311911A (zh) | 一种尼拉帕尼的手性中间体的制备方法 | |
CN105968103A (zh) | 抗肿瘤药物阿法替尼的合成方法 | |
CN103242245B (zh) | 坦度替尼的制备方法 | |
CN102070513A (zh) | 1-叔丁氧羰基-4-哌啶酮的合成方法 | |
CN103275020A (zh) | 厄洛替尼的制备方法 | |
CN103408551B (zh) | 阿立塞替的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: XU XUENONG Effective date: 20150813 Owner name: ZHEREN PHARMACEUTICAL NANJING CO., LTD. Free format text: FORMER OWNER: SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. Effective date: 20150813 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150813 Address after: 211806 Qiaolin Industrial Park, Pukou District, Jiangsu, Nanjing, China, 32-71 Patentee after: A pharmaceutical Nanjing Co.,Ltd. Address before: 215000 Jiangsu Province, Suzhou City Industrial Park Commercial Plaza Building 1 room 1305 Lianfeng Patentee before: SUZHOU MIRACPHARMA TECHNOLOGY Co.,Ltd. Patentee before: Xu Xuenong |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170111 Address after: 215000 Jiangsu province Suzhou Industrial Park Commercial Plaza Building 1 room 1305 Lianfeng Patentee after: SUZHOU MIRACPHARMA TECHNOLOGY Co.,Ltd. Address before: 211806 Qiaolin Industrial Park, Pukou District, Jiangsu, Nanjing, China, 32-71 Patentee before: A pharmaceutical Nanjing Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20200103 Address after: 629000 Industrial Development Zone, Daying County, Sichuan City, Suining Province Patentee after: SICHUAN JUST RUBBER Co.,Ltd. Address before: Room 1305, building 1, Lianfeng Commercial Plaza, Suzhou Industrial Park Patentee before: SUZHOU MIRACPHARMA TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200414 Address after: No. 403, Zone G, No. 8, Beida South Road, xixiantang District, Nanning City, Guangxi Zhuang Autonomous Region, 530000 Patentee after: Guangxi Dingrui Technology Service Co.,Ltd. Address before: 629000 Industrial Development Zone, Daying County, Sichuan City, Suining Province Patentee before: SICHUAN JUST RUBBER Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200519 Address after: 223001 room 2303, building 1, new century Haoyuan, Qinghe District, Huai'an City, Jiangsu Province Patentee after: Jiangsu Qianyuan Construction Co.,Ltd. Address before: No. 403, Zone G, No. 8, Beida South Road, xixiantang District, Nanning City, Guangxi Zhuang Autonomous Region, 530000 Patentee before: Guangxi Dingrui Technology Service Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150121 |
|
CF01 | Termination of patent right due to non-payment of annual fee |